Department of General Surgery, The George Washington University Medical Center, Washington, DC, USA.
Surg Endosc. 2011 Jun;25(6):1962-8. doi: 10.1007/s00464-010-1494-z. Epub 2010 Dec 22.
Type 2 diabetes (T2D) resolves rapidly after bariatric surgery, even before substantial weight is lost. However, the molecular pathways underlying this phenomenon remain unclear. Microarray data has shown that numerous genes are differentially expressed in blood after bariatric surgery, including resistin and leptin. Resistin and leptin are circulating hormones derived from adipose tissue, which are associated with obesity and insulin resistance. This study examined expression of these genes before and after bariatric surgery in diabetic and nondiabetic obese patients.
The study included 16 obese patients who underwent bariatric surgery, either Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding. Eight patients had T2D. Preoperative blood samples were collected in PAXgene tubes to stabilize mRNA. Postoperative samples were collected 3 months after surgery. Total RNA was isolated and cDNA was synthesized. Real-time quantitative PCR was used to quantify mRNA. Results were analyzed using Student's t test with a P<0.05 considered significant.
Postoperatively, five diabetic patients had discontinued hypoglycemic medications and one showed improved glycemic control. Both leptin and resistin mRNA levels were elevated in the diabetic group but decreased after surgery to levels near those of the nondiabetic group. Greater downregulation of resistin and leptin expression occurred in patients who lost more excess body weight (EBW), while patients who lost less than 10% EBW had a mean increase in expression of the two genes. Downregulation of both genes was more pronounced after RYGB compared to gastric banding.
Downregulation of resistin and leptin gene expression after bariatric surgery may play a role in normalizing obesity-associated insulin resistance. Interestingly, downregulation is greater after RYGB and in patients who lose a greater proportion of EBW. Targeted therapies for obesity and diabetes may be developed by understanding the pathways by which these adipocytokines contribute to obesity and T2D.
即使在体重显著减轻之前,减重手术后 2 型糖尿病(T2D)也会迅速缓解。然而,这一现象背后的分子途径仍不清楚。微阵列数据显示,减重手术后血液中有许多基因表达不同,包括抵抗素和瘦素。抵抗素和瘦素是源自脂肪组织的循环激素,与肥胖和胰岛素抵抗有关。本研究在糖尿病和非糖尿病肥胖患者中检查了这些基因在减重手术前后的表达。
该研究包括 16 名接受减重手术的肥胖患者,手术方式为 Roux-en-Y 胃旁路术(RYGB)或可调胃束带术。8 名患者患有 T2D。术前采集 PAXgene 管中的血液样本以稳定 mRNA。术后样本在手术后 3 个月采集。提取总 RNA 并合成 cDNA。采用实时定量 PCR 定量 mRNA。采用 Student's t 检验分析结果,P<0.05 为差异有统计学意义。
手术后,五名糖尿病患者停止使用降糖药物,一名患者血糖控制得到改善。糖尿病组的瘦素和抵抗素 mRNA 水平均升高,但手术后下降至接近非糖尿病组的水平。在体重减轻更多的患者中,抵抗素和瘦素表达的下调更为明显,而体重减轻不足 10%的患者这两种基因的表达平均增加。与胃束带术相比,RYGB 后两种基因的下调更为明显。
减重手术后抵抗素和瘦素基因表达的下调可能在肥胖相关胰岛素抵抗的正常化中起作用。有趣的是,RYGB 后和体重减轻更多的患者下调更为明显。通过了解这些脂肪细胞因子在肥胖和 T2D 中的作用途径,可能开发出针对肥胖和糖尿病的靶向治疗方法。